الفهرس 
REVIEW OF LITERATUREOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
Psoriatic arthritis is a chronic, inflammatory joint and connective tissue disease, associated with psoriasis (Ps), with potential for significant joint destruction leading to pain and disability. PsA is classified as a distinct form of inflammatory arthritis and is a subset of seronegative SpA.
Fibromyalgia is an idiopathic, chronic, non-articular pain syndrome defined by widespread musculoskeletal pain and generalized tender points. Other common symptoms include sleep disturbances, fatigue, headache, morning stiffness, paresthesias, and anxiety.
Psoriatic arthritis is a progressive disease that is also associated with fatigue, emotional disturbance, and poor HRQOL. These manifestations may overlap with those of FM. Furthermore, it is well known that FM commonly co-exist with various rheumatic diseases.
The aim of the present study was to evaluate the effect of secondary FM on the disease activity indices in PsA patients.
Sixty PsA patients were included in this study, and classified into 2 groups based on the absence or presence of associated FM according to the 2016 Revisions to the 2010/2011 FM diagnostic criteria. group (Ι): PsA only patients, and group (ΙI): patients with PsA and concomitant FM (PsA-FM).
Each patient was subjected to history taking including duration of both Ps and PsA, complete clinical examination with stress on the musculoskeletal system, assessment of PsA disease activity, secondary outcome measures and assessment of FM.
The study revealed the following results: There were statistically significant differences between two groups regarding the subjective assessment measures; TJC, DAPSA, CPDAI, PASI, LEI, BASDAI, ASQOL, MAF scores. While the objective assessment measures of inflammation; including CRP, SJC and dactylitis count, showed no statistically significant difference between the 2 groups.
These results might highlight the influence of the co-existence of FM in PsA. It should be taken into consideration in the treatment algorithm to avoid unnecessary upgrading of treatment.